Equity / Investment · MENA · Announced 21 Oct 2026
RMBV → ATCO Pharma
Equity / Investment deal between RMBV (Egypt) and ATCO Pharma (Egypt), announced 21 Oct 2026. Value: Undisclosed.
Parties: RMBV (RNAF III — North Africa Fund III) (Egypt) → ATCO Pharma for Pharmaceutical Industries S.A.E. (Egypt)
- Deal type
- Equity / Investment
- Value
- Undisclosed
- Territory
- Egypt (domestic anchor); regional and international expansion targeted across MENA and beyond
- Asset
- ATCO Pharma — human + veterinary pharmaceutical manufacturing platform (founded 1986)
- Announced
- 21 Oct 2026
Our analysis
Why this matters.
RMBV — the Cairo-based mid-cap investor behind North Africa Fund III — has signed definitive agreements to take a joint-control stake in ATCO Pharma , a 40-year-old Egyptian manufacturer of human and veterinary medicines. It is RNAF III's first investment in the veterinary pharmaceutical sector , and one of the clearest expressions yet of institutional capital moving into Egypt's family-founded drug manufacturing base.
The full analysis is free to read with a work email on this page.
Source: Zawya